You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Adults Rheumatoid Arthritis, Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). ERELZI can be used in combination with methotrexate. Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. Psoriatic Arthritis, The signs and symptoms of active and progressive psoriatic arthritis (PsA) in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. ERELZI has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Plaque Psoriasis, Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. Ankylosing Spondylitis, The signs and symptoms of active ankylosing spondylitis (AS) in adults. Non-radiographic Axial Spondyloarthritis, Treatment of adults with active* non-radiographic axial spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs. *Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of = 4. Children and Adolescents, Paediatric patients weighing less than 62.5 kg should not receive ERELZI. Paediatric patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis with other etanercept products. Juvenile Idiopathic Arthritis, Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs. Active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. Active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. Etanercept has not been studied in children aged less than 2 years. Paediatric Plaque Psoriasis, Chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant PASI response is not achieved.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
